-
Press Registration Is Now Open For The 2025 ACMG Annual Clinical Genetics Meeting
17 Dec 2024 18:35 GMT
… artificial intelligence in genetics, gene editing, reproductive genetics, cancer genetics, direct-to … the study of genetics, biochemical/metabolic genetics, genetic counseling, health … How Low is Low Enough? (BioMarin)
*NEW* ACMG Foundation Corporate …
-
BioMarin to Increase Production Capacity with €60 Million Expansion at Ireland Facility
13 Dec 2024 14:29 GMT
… scale for people living with genetic conditions. This latest investment … Dec. 9, 2024.
2. BioMarin Pharmaceutical. BioMarin Agrees to Acquire Biologics Manufacturing … April 24, 2023.
4. BioMarin Pharmaceutical. Products. biomarin.com/products-and …
-
BioMarin announces significant investment and expansion of Cork facility
09 Dec 2024 07:52 GMT
… Vice President, Chief Quality Officer, BioMarin Pharmaceutical. “The Shanbally facility … President of Shanbally Manufacturing Operations, BioMarin Pharmaceutical said, “Expanding our … scale for people living with genetic conditions. This latest investment …
-
BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024
16 Nov 2024 16:12 GMT
… -to-treat genetic conditions. To learn more, please visit www.biomarin.com … BioMarin's plans and expectations for clinical trials for various genetic … information, future events or otherwise.
BioMarin®, BioMarin RareConnections® and VOXZOGO® are registered …
-
BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook
30 Oct 2024 17:49 GMT
… 4980126
Conference ID: 4980126
About BioMarin
BioMarin is a global biotechnology company … treat genetic conditions. To learn more, please visit www.biomarin.com … the business prospects of BioMarin Pharmaceutical Inc. (BioMarin), including, without limitation, …
-
BioMarin Surpasses Analysts’ Q3 Sales Estimates Despite Voxzogo’s Slight Miss
30 Oct 2024 12:46 GMT
… of its therapies for rare genetic diseases.
The biotech beat … analyst Joon Lee also credited BioMarin’s Sanofi-partnered enzyme … continued growth of its products—BioMarin on Tuesday raised its … billion this year.
Despite BioMarin’s promising outlook for 2024 …
-
Advances in Genetic Engineering Driving Gene Therapy Market at 21.4% CAGR by 2031
11 Oct 2024 13:07 GMT
… public awareness and knowledge, genetic testing is becoming increasingly important … investigate gene therapies for rare genetic diseases, capitalizing on their … US)
• bluebird bio, Inc. (US)
• BioMarin Pharmaceutical Inc. (US)
• Krystal Biotech …
-
CAMP4 Enters Strategic Research Collaboration to Advance Novel Regulatory RNA-Targeting Medicines for Rare Genetic Conditions
01 Oct 2024 11:00 GMT
… genetic diseases, today announced a new research collaboration with BioMarin … , said, “BioMarin is a leader in genetic medicines with a … for patients with rare genetic conditions. We believe this … a broad range of genetic diseases where amplifying healthy …
-
BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish
25 Sep 2024 19:54 GMT
… children with achondroplasia, a genetic disorder that causes dwarfism … Read: Rare Disease-Focused BioMarin Narrows Sales Focus, Cuts … upside and diversification beyond BioMarin's guidance. Nonetheless … increasing competitive pressure on BioMarin's key …
-
Gene Therapy Market Industry Trends and Forecasts to 2035 - Global Gene Therapy Market Forecast to Surge to $9.2 Billion by 2035 Amidst Advances in Genetic Science - ResearchAndMarkets.com
24 Sep 2024 14:25 GMT
… abnormalities and inherited genetic mutations, including autoimmune disorders, genetic disorders, neurological … Companies
Amgen
Artgen Biotech
BioMarin Pharmaceutical
bluebird bio
CRISPR … in North America
Amgen
BioMarin Pharmaceutical
bluebird bio
CRISPR …
About
© 1995-2025